The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
== Function == This gene encodes the alpha chain of type XVI collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. High levels of type XVI collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion.
=== Lung disease === Active alveolitis is often treated with pulses of cyclophosphamide, often together with a small dose of steroids. The benefit of this intervention is modest. Pulmonary hypertension may be treated with epoprostenol, treprostinil, bosentan, and possibly aerolized iloprost. Nintedanib was approved for use in the United States Food and Drug Administration on September 6, 2019, to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
=== Sjögren's disease === Sjögren's disease is a long-term autoimmune disease that affects the body's moisture-producing glands (lacrimal and salivary), and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.
== Protein degradation == Protein degradation differs from protein catabolism. Proteins are produced and destroyed routinely as part of the normal operations of the cell. Transcription factors, proteins that help regulate protein synthesis, are targets of such degradations. Their degradation is not a significant contributor to the energy needs of the cell. The addition of ubiquitin (ubiquitylation) marks a protein for degradation via the proteasome.
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Sources: en.wikipedia.org
On October 10, Trump had another visit with Walter Reed. Leavitt described the visit as a "routine yearly checkup", despite it being Trump's second at the facility in a six-month-period. Barbabella did not elaborate on the imaging or "preventive assessments" that he performed, but added that Trump's laboratory results were "exceptional," and that his cardiac age is "approximately 14 years younger than his chronological age." On October 27, Trump told reporters that he had undergone an undisclosed MRI scan during a previous visit to Walter Reed, which, despite his claim that it gave "some of the best reports for the age" and "some of the best reports they've ever seen", led to further speculation about his health due to the undisclosed nature of why he had the procedure done. Trump also bragged about his taking of the MoCA test, again misidentifying the screening assessment for detecting cognitive impairment as a "very hard [...] IQ test" and claiming that younger Democratic political opponents do not have the intelligence to pass it. Whether a third MoCA test was conducted during the October visit or if Trump was referring to his April 2025 and/or January 2018 assessments was not clarified. On October 28, new concerns about Trump's mental state were raised when a video emerged of him wandering off while walking alongside Sanae Takaichi, the first female prime minister of Japan, while at Akasaka Palace in Tokyo, Japan.
=== Cellular uptake mechanisms === After nanogels exit the vasculature, they diffuse through the interstitial space into their target tissue. At the cellular level, nanogels can be internalized by a large number of different types of endocytosis that depend on the particle's size, shape, and surface properties. Endocytosis is the most common mechanism that starts with the nanogels engulfed by the cellular membrane. The nanogels are transported in intracellular vesicles for delivery to endosomes that eventually combine with lysosomes. Once lysosomes are released into the cytosol of a cell, they deliver their cargo immediately or move to the appropriate cellular compartment.
=== Reversibility === Minimal intervention, reversibility, and future treatability are core principles of contemporary conservation. Adhesive treatments that have failed or exceeded their lifespan may need to be removed, which may compromise or further damage delicate textiles. Because affixed supports can affect a fabric's drape or hand, and reversibility is not assured, conservators should evaluate alternative methods before proceeding with treatment. Despite these factors, adhesive consolidation is often the only option for severely damaged textiles. As with all types of treatment, conservators need to find a balance between intervention and potential loss of the artifact, a decision that requires a thoughtful weighing of risks and assessment of the post-treatment consequences. Some alternatives to adhesive consolidation include crepeline encapsulation, pressure mounts, and customized non-vertical display systems.
=== Blood pressure === An early study showed that the intravenous injection of propionic acid into mice induced a brief (<5 min) hypotensive response as defined by drops in their mean arterial pressures. This response was reduced in mice that had one of their two Ffar3 genes knocked out and absent in mice that had both Ffar3 genes knocked out. A subsequent study reported that Ffar3 gene knockout mice developed abnormally high pulse pressures (i.e., systolic minus diastolic blood pressures) as well as increased amounts of cardiac collagen and elastin connective tissue and increased cardiac stiffness as evidenced by a reduced rate of heart muscle relaxation measured by pressure-volume loop analysis tau levels.
Sources: en.wikipedia.org
One contemporary news article claimed the murder was related to "the demoniac rites of West African savages, from whom Voodoo practices were transferred to West Indian Negroes, and from them to the United States."
== See also == Drug design Drug metabolism Microbial biodegradation Biodegradation Bioremediation Antioxidant SPORCalc, an example process for exploring xenobiotic and drug metabolism databases Archived 2009-03-18 at the Wayback Machine
=== Comparative effectiveness === A major systematic review and network meta-analysis of medications for the treatment of insomnia was published in 2022. It found a widely varying range of effect sizes (standardized mean difference or SMD) in terms of clinical effectiveness for insomnia. The assessed medications and their effect sizes included benzodiazepines (e.g., temazepam, triazolam, many others) (SMDs 0.58 to 0.83), Z-drugs (eszopiclone, zaleplon, zolpidem, zopiclone) (SMDs 0.03 to 0.63), sedative antidepressants and antihistamines (doxepin, doxylamine, trazodone, trimipramine) (SMDs 0.30 to 0.55), the antipsychotic quetiapine (SMD 0.07), orexin receptor antagonists (daridorexant, lemborexant, seltorexant, suvorexant) (SMDs 0.23 to 0.44), and melatonin receptor agonists (melatonin, ramelteon) (SMDs 0.00 to 0.13). The certainty of evidence varied and ranged from high to very low depending on the medication. Certain medications often used as hypnotics, including the antihistamines diphenhydramine, hydroxyzine, and promethazine and the antidepressants amitriptyline and mirtazapine among others, were not included in analyses due to insufficient data.
The sum of these two frequencies is the cyclotron frequency, which depends only on the ratio of electric charge to mass and on the strength of the magnetic field. This frequency can be measured very accurately and can be used to measure the masses of charged particles. Many of the highest-precision mass measurements (masses of the electron, proton, 2H, 20Ne and 28Si) come from Penning traps. Buffer gas cooling, resistive cooling, and laser cooling are techniques to remove energy from ions in a Penning trap. Buffer gas cooling relies on collisions between the ions and neutral gas molecules that bring the ion energy closer to the energy of the gas molecules. In resistive cooling, moving image charges in the electrodes are made to do work through an external resistor, effectively removing energy from the ions. Laser cooling can be used to remove energy from some kinds of ions in Penning traps. This technique requires ions with an appropriate electronic structure. Radiative cooling is the process by which the ions lose energy by creating electromagnetic waves by virtue of their acceleration in the magnetic field. This process dominates the cooling of electrons in Penning traps, but is very small and usually negligible for heavier particles. Using the Penning trap can have advantages over the radio frequency trap (Paul trap). Firstly, in the Penning trap only static fields are applied and therefore there is no micro-motion and resultant heating of the ions due to the dynamic fields, even for extended 2- and 3-dimensional ion Coulomb crystals.
== Articles == Reduce waste with shelf-life indicator for food, The Research Council of Norway, The Food Programme, 1 September 2010[link removed] Less Waste With Shelf-Life Indicator for Food, Science Daily, 1 September 2010 TimeTemp's shelf-life indicator for food will help Norwegian retailers reduce waste, News Medical, 4 September 2010 Intelligent shelf life indicator could slash food waste, FoodProduction daily.com, 7 September 2010 TimeTemp bring waste solution with intelligent shelf-life indicator in-Pharma Technologist.com, 9 September 2010 TimeTemp develops smart label, Bakers Journal, 15 November 2010[link removed]
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.